Abstract: An engine support truss assembly for aircraft includes a mounting plate having a front side and a back side opposite the front side, a truss structure mechanically coupled to the front side of the mounting plate, and a backup structure mechanically coupled to the back side of the mounting plate. The truss structure includes a plurality of structural members each including precipitation-hardened stainless steel. The backup structure is configured to provide mechanical support to the truss structure.

Abstract: A method, system, apparatus, and computer program product provide the ability to augment an as-built model. A CAD drawing of a project as well as a digital representation of a physical implementation of the project are obtained. A relationship that maps the digital representation to the CAD drawing is defined/established. A component of the digital representation is identified based on the relationship (e.g., and a database/catalog). Information about the identified component is transmitted to and displayed on a computer (e.g., a mobile device).

Abstract: A method, system, apparatus, and computer program product provide the ability to augment an as-built model. A CAD drawing of a project as well as a digital representation of a physical implementation of the project are obtained. A relationship that maps the digital representation to the CAD drawing is defined/established. A component of the digital representation is identified based on the relationship (e.g., and a database/catalog). Information about the identified component is transmitted to and displayed on a computer (e.g., a mobile device).

Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.

Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.

Abstract: The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.

Abstract: A hemofiltration system and method to treat an Inflammatory Mediator Related Disease in a mammal, including chronic and acute diseases, include a hemofilter and an adsorptive device. The hemofilter removes ultrafiltrate from a blood stream extracted from the mammal to create a filtered blood stream and an ultrafiltrate stream. The adsorptive device may include one or more adsorbent materials and may be used to adsorb inflammatory mediators from the ultrafiltrate stream received from the hemofilter to create a post adsorption ultrafiltrate stream. The post adsorption ultrafiltrate stream may be selectively combined with the filtered blood stream and together with the filtered blood stream may be returned to the mammal.

Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.

Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.

Abstract: A method, apparatus, and article of manufacture for enabling the creation of authorable, dynamic software objects. An apparatus made in accordance with the present invention comprises a computer and an attached monitor, stream means, display property means, display representation means, and display configuration means. The stream means is performed by the computer and accepts at least one graphic primitive into the software object. The display property means is performed by the computer and stores at least one quality associated with each graphic primitive in the software object. The display representation means is performed by the computer and graphically represents a selected set of display properties of the software object. The display configuration means is performed by the computer and selectively displays one of the sets of graphical representations of the software object on the monitor of the computer.

Abstract: The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.

Abstract: Addition of certain tryptophan analogs to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of new rebeccamycin analogs having advantageous antitumor properties.

Abstract: A new antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.

Abstract: An antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.

Abstract: Addition of bromine to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of a new rebeccamycin derivative having advantageous antineoplastic properties.

Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.

Abstract: Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.

Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.

Abstract: Actinomadura melliaura nov. sp. (ATCC 39691) produces four novel compounds which we have designated AT 2433 A.sub.1, AT 2433 A.sub.2, AT 2433 B.sub.1 and AT 2433 B.sub.2. The novel compounds or pharmaceutically acceptable salts thereof exhibit antibacterial and antitumor activity.

Abstract: A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.